Investors

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities.
More>>
Featured Reports
2014 Annual Report on Form 10-K  - PDF 2014 Annual Report on Form 10-K
Fact Sheet - PDF Fact Sheet
OSUR (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$5.40
Change (%)0.00 (0.00%)
Volume0
Data as of 08/31/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
08/28/15OraSure Technologies Announces 2016 Annual Meeting Date
BETHLEHEM, Pa., Aug. 28, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that its 2016 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 17, 2016. Further details regarding the meeting will be provided at a later date. About OraSure Technologies OraSure Technologies is a leader in the development, manufacture and distribution of point-of-care diagnostic and collection devices and other technologies designed to detect or diagnose crit... 
Printer Friendly Version
08/05/15OraSure Announces 2015 Second Quarter Financial Results
BETHLEHEM, Pa., Aug. 5, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the three and six months ended June 30, 2015. Financial Highlights Consolidated net revenues for the second quarter of 2015 were a record $30.4 million, a 15% increase from the comparable quarter of 2014. Consolidated net revenues for the six months ended June 30, 2... 
Printer Friendly Version
08/04/15OraSure Technologies to Present at the Canaccord Genuity 35th Annual Growth Conference
BETHLEHEM, Pa., Aug. 4, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Canaccord Genuity 35th Annual Growth Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak August 12, 2015, at approximately 2:00 PM Eastern ... 
Printer Friendly Version
08/03/15Orasure Technologies Receives FDA Emergency Use Authorization for Ebola Rapid Diagnostic Test
BETHLEHEM, Pa., Aug. 3, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, announced today that it has received a U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its OraQuick® Ebola Rapid Antigen Test for use with fingerstick and venous whole blood. This test has not been cleared or approved by FDA. This test has been authorized by FDA under an EUA for use by laboratories... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
05/17/16
OraSure Technologies, Inc. Annual Shareholder Meeting
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources



Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet